About Outlook Therapeutics, Inc. - Common Stock (OTLK)
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company specializes in the research and advancement of therapies aimed at addressing significant unmet medical needs in ophthalmology. Through its proprietary drug pipeline, Outlook Therapeutics is committed to enhancing the quality of life for patients affected by various retinal conditions, striving to bring new possibilities and improved outcomes to vision care. Read More
The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.
Outlook Therapeutics shares fall after the FDA rejects its ONS-5010 wet AMD drug application, citing insufficient efficacy evidence despite prior trial success.
